Performances of Clinical Disease Activity Index (<scp>CDAI</scp>) and Simplified Disease Activity Index (<scp>SDAI</scp>) appear to be better than the gold standard Disease Assessment Score (<scp>DAS</scp>‐28‐<scp>CRP</scp>) to assess rheumatoid arthritis patients

Dhaon, Pooja; Das, Siddharth Kumar; Srivastava, Ragini; Dhakad, Urmila

doi:10.1111/1756-185x.13110

Cited by 33 publications

(32 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The proportion of females was higher than males and the average age of the patients was 51.93±14.2, with a mean 4.78±3.60 years of disease duration. These findings was comparative to previous studies [8][9][10]. Prabhakaran AP et al, had a high CDAI score in 60% of their cases.…”

Section: Discussionsupporting

confidence: 62%

Cardio-Respiratory Manifestations and Its Correlation with Clinical Disease Activity Index in Rheumatoid Arthritis

Yadav¹,

Jotkar²

2020

SASJM

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 62%

Cardio-Respiratory Manifestations and Its Correlation with Clinical Disease Activity Index in Rheumatoid Arthritis

Yadav¹,

Jotkar²

2020

SASJM

View full text Add to dashboard Cite

“…However, in the latter the disease remission was based on DAS28‐CRP < 2.6, 9 which is a less stringent cut‐off of SDAI remission adopted in our study. SDAI remission, as suggested by ACR/EULAR recommendations, 1 is associated with lowest risk of x‐ray progression and residual subclinical inflammation 2,10‐12 . Furthermore, 4 out of 6 ‘steroid‐yes’ patients stopped the first bDMARD for loss of efficacy but regained SDAI remission after switching to a bDMARD with a different mechanism of action.…”

Section: Discussionmentioning

confidence: 99%

Predictors of long‐term clinical remission in rheumatoid arthritis

Fornaro

Cacciapaglia

Lopalco

et al. 2020

Eur J Clin Investigation

View full text Add to dashboard Cite

Aim Little is known about possible predictors of long‐term survival on biologic disease‐modifying antirheumatic drugs (bDMARD) after achievement of deep clinical remission in rheumatoid arthritis (RA) patients. We aimed at assessing factors associated with drug persistence of the first bDMARD in RA patients who achieved Simplified Disease Activity Index (SDAI) remission. Methods The clinical charts of RA patients beginning a first bDMARD were retrospectively reviewed, and those who achieved SDAI‐based remission were selected for this analysis. Drug retention rate and mean survival time (MST) were estimated using Kaplan‐Meier curves, and hazard ratios (HRs) of discontinuing bDMARD were estimated by multivariate Cox‐regression models. Results Eight‐six patients were on SDAI remission, and the survival rate of bDMARDs since ‘baseline‐time’ was 82.6% (MST = 77.8 (95% CI: 69‐86) months). Once on remission, patients not taking concomitant glucocorticoids had significantly higher survival rate (90.7%, MST = 86.3 (95% CI: 78‐95) months) than patients who continued to intake low dose of glucocorticoids (68.8%, MST = 56.9 (95% CI: 45‐69) months; P = .008). On the contrary, those patients assuming methotrexate (MTX) had significantly higher survival (87.7% (MST = 81.8 (95% CI: 73‐91) months) than patients who were not taking MTX (66.7% (MST = 55.3 (95% CI: 40‐71) months) (log‐rank 4.72, P = .03). After the achievement of disease remission, stopping glucocorticoids (HR 0.31, 95% CI: 0.10‐0.93) and methotrexate co‐therapy (HR 0.34, 95% CI: 0.12‐0.98) were independently associated with a lower risk of bDMARD discontinuation. Conclusions Among RA patients on clinical remission with a first bDMARD, those stopping glucocorticoids and continuing MTX had much longer survival on bDMARD.

show abstract

“…We defined patients as biologic disease‐modifying anti‐rheumatic drugs (bDMARDs)‐refractory on the date they had started their third class of bDMARDs before enrolment into the study . The degree of activity of RA disease was evaluated by the clinical disease activity index (CDAI) score . Patients with a CDAI score >10 were defined as subjects with activated pattern of the disease having moderate‐high disease activity, those with CDAI score >22 having high disease activity .…”

Section: Methodsmentioning

confidence: 99%

Usefulness of CHA₂DS₂‐VASc score to predict mortality and hospitalization in patients with inflammatory arthritis

et al. 2019

View full text Add to dashboard Cite

Background: Inflammatory arthritis including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are disorders at increased risk of morbidity and mortality for which a validated prognostic tool for facilitating clinical management is needed. CHA 2 DS 2 -VASc (congestive heart failure/hypertension/age diabetes/stroke/vascular disease/age/sex category) score was initially conceived and used to estimate thromboembolic risk in non-valvular atrial fibrillation, and then successfully applied in community populations with sinus rhythm. We tested CHA 2 DS 2 -VASc-score as a prognosticator of adverse outcomes in patients in sinus rhythm with RA/AS/PsA. Methods: Between March 2014 and March 2015, 414 patients (214 RA, 75 AS, 125PsA) in sinus rhythm without cardiac disease were consecutively analyzed and prospectively followed-up. Primary and co-primary end-points were a composite of allcause death/all-cause hospitalization and CV death/CV hospitalization, respectively.Results: Patients were divided into LOWscore and HIGHscore groups if CHA 2 DS 2 -VASc was = 0/1 point or greater than 1 point, respectively. The HIGHscore group comprised 190 patients who were older with higher prevalence of CV risk factors and arthritis disease activity than 224 LOWscore patients. During a follow up of 36 months, the event rate for primary and co-primary end-point was 37% and 12% in the HIGHscore vs 22% and 4% in LOWscore group (P = .001 and .002 respectively).At multivariate Cox regression analysis CHA 2 DS 2 -VASc-score was related to primary end-point (hazards ratio [HR] 1.30 [1.07-1.59], P = .009) and co-primary end-point (HR 1.35 [1.01-1.79], P = .04) independently of traditional CV risk factors analyzed individually and indexes of inflammation or disease duration. Conclusion: CHA 2 DS 2 -VASc-score accurately identifies in the mid-term patients in sinus rhythm with RA/AS/PsA at different risks for CV and non-CV mortality and hospitalization. K E Y W O R D S ankylosing spondylitis, cardiovascular risk factors, CHA 2 DS 2 -VASc score, clinical outcomes, psoriatic arthritis, rheumatoid arthritis | 107 CIOFFI et al.

show abstract

Performances of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS‐28‐CRP) to assess rheumatoid arthritis patients

Abstract: The study shows an excellent strong positive correlation between DAS-28-CRP, CDAI and SDAI at initial evaluation but not at final visit. SDAI- and CDAI-based remission criteria seem to be better than DAS-28-CRP-based remission criteria.

Cited by 33 publications

References 20 publications

Cardio-Respiratory Manifestations and Its Correlation with Clinical Disease Activity Index in Rheumatoid Arthritis

Cardio-Respiratory Manifestations and Its Correlation with Clinical Disease Activity Index in Rheumatoid Arthritis

Predictors of long‐term clinical remission in rheumatoid arthritis

Usefulness of CHA₂DS₂‐VASc score to predict mortality and hospitalization in patients with inflammatory arthritis

Contact Info

Product

Resources

About

Performances of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS‐28‐CRP) to assess rheumatoid arthritis patients

Abstract: The study shows an excellent strong positive correlation between DAS-28-CRP, CDAI and SDAI at initial evaluation but not at final visit. SDAI- and CDAI-based remission criteria seem to be better than DAS-28-CRP-based remission criteria.

Cited by 33 publications

References 20 publications

Cardio-Respiratory Manifestations and Its Correlation with Clinical Disease Activity Index in Rheumatoid Arthritis

Cardio-Respiratory Manifestations and Its Correlation with Clinical Disease Activity Index in Rheumatoid Arthritis

Predictors of long‐term clinical remission in rheumatoid arthritis

Usefulness of CHA2DS2‐VASc score to predict mortality and hospitalization in patients with inflammatory arthritis

Contact Info

Product

Resources

About

Usefulness of CHA₂DS₂‐VASc score to predict mortality and hospitalization in patients with inflammatory arthritis